General MedicationsINJECTIONGeneric
NOVANTRONE
MITOXANTRONE HYDROCHLORIDE
Standard Dose
EQ 2MG BASE/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview NOVANTRONE is listed in Drugs@FDA under application 021120 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient MITOXANTRONE HYDROCHLORIDE Form and strength INJECTABLE; INJECTION - EQ 2MG BASE/ML Sponsor SERONO INC Submission history Latest submission status date: 2000-10-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview NOVANTRONE is listed in Drugs@FDA under application 021120 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient MITOXANTRONE HYDROCHLORIDE Form and strength INJECTABLE; INJECTION - EQ 2MG BASE/ML Sponsor SERONO INC Submission history Latest submission status date: 2000-10-13 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.